⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Myostatin Inhibitors
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-03 — Myostatin inhibitors and the paradox of larger but weaker muscles: Peter Attia (podcast/media commentary) frames the class-wide paradox: both older and newer myostatin-pathway inhibitors can preserve or increase lean mass without reliably improving muscle strength — expert synthesis of existing trial readouts, not a new study. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Myostatin inhibitors and the paradox of larger but weaker muscles
03-oct-2026
novelty 3
per-area 3
strengthens